#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3384	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2693	372.4	0	.	n	.	0	A69G	SNP	69	69	A	699	699	G	480	G,A	447,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3384	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2693	372.4	0	.	n	.	0	C1450T	SNP	1450	1450	C	2080	2080	T	451	T,C	417,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3384	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2693	372.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1814	1814	C	480	C,A	438,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3384	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2693	372.4	0	HET	.	.	.	C1358T	.	1358	1358	C	1988	1988	C	454	C,T	315,94	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5440	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4076	400.1	0	.	n	.	0	T695C	SNP	695	695	T	1265	1265	C	440	C	395	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5440	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4076	400.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2541	2541	C	499	C,T	453,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5440	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4076	400.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3167	3167	T	427	T,C	389,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5440	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4076	400.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2615	2615	A	513	A,C	460,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	590	folP	855	855	100.0	folP.l15.c4.ctg.1	2147	82.5	1	SNP	p	R229S	1	.	.	685	687	AGC	1335	1337	AGC	114;115;115	A;G;C,A	102;104;104,1	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1160	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	4019	86.4	1	SNP	p	S91F	1	.	.	271	273	TTC	863	865	TTC	109;109;109	T;T;C	102;100;101	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1160	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	4019	86.4	1	SNP	p	G95N	0	.	.	283	285	GGC	875	877	GGC	106;106;106	G;G;C,A	97;98;95,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1160	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	4019	86.4	1	SNP	p	D95G	1	.	.	283	285	GGC	875	877	GGC	106;106;106	G;G;C,A	97;98;95,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	510	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1888	81.2	0	.	p	.	0	D79N	NONSYN	235	237	GAT	893	895	AAT	145;145;145	A;A;T	132;134;127	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	510	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1888	81.2	1	SNP	p	G45D	0	.	.	133	135	GGC	791	793	GGC	150;151;152	G;G,A;C	137;137,1;135	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	304	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1423	63.6	0	.	n	.	0	A197.	DEL	197	197	A	739	739	A	125	A	116	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1214	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3445	105.6	0	.	p	.	0	E91G	NONSYN	271	273	GAG	756	758	GGG	117;118;118	G;G;G	105;106;102	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1214	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3445	105.6	1	SNP	p	D86N	0	.	.	256	258	GAC	741	743	GAC	123;122;122	G;A;C	107;99;105	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1214	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3445	105.6	1	SNP	p	S87W	0	.	.	259	261	AGT	744	746	AGT	120;118;118	A,G,C;G;T	103,1,1;106;105	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1214	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3445	105.6	1	SNP	p	S87I	0	.	.	259	261	AGT	744	746	AGT	120;118;118	A,G,C;G;T	103,1,1;106;105	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1214	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3445	105.6	1	SNP	p	S87R	0	.	.	259	261	AGT	744	746	AGT	120;118;118	A,G,C;G;T	103,1,1;106;105	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1214	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3445	105.6	1	SNP	p	S88P	0	.	.	262	264	TCC	747	749	TCC	118;119;119	T;C;C	102;106;109	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1034	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3248	95.4	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1895	1897	CAC	110;111;112	C,G;A,G;C	100,1;97,1;103	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1034	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3248	95.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1844	1846	GGC	113;113;112	G;G;C	103;98;97	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.44.001	penA.44.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2877	101.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1522	1524	GCA	156;155;156	G,C;C;A	141,1;139;140	penA.44.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2877	101.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1525	1527	ATC	156;157;157	A;T;C	145;141;142	penA.44.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2877	101.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1537	1539	GTG	150;150;152	G;T;G,A	139;139;139,1	penA.44.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2877	101.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1537	1539	GTG	150;150;152	G;T;G,A	139;139;139,1	penA.44.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2877	101.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2041	2043	ACC	116;115;115	A;C;C	103;101;102	penA.44.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2877	101.0	1	SNP	p	T502V	0	.	.	1504	1506	ACG	2095	2097	ACG	105;105;105	A;C;G	85;90;84	penA.44.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2877	101.0	1	SNP	p	T502P	0	.	.	1504	1506	ACG	2095	2097	ACG	105;105;105	A;C;G	85;90;84	penA.44.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2877	101.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2218	2220	GGC	114;115;114	G,A;G;C	99,1;99;101	penA.44.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2877	101.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2227	2229	GGC	117;116;117	G,T;G;C	100,1;104;98	penA.44.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	972	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2877	101.0	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2245	2247	CTG	112;112;112	C,G;T;G	99,1;99;96	penA.44.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1288	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3545	108.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1822	1824	CCG	134;133;132	C;C;G,T	112;112;110,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	596	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2219	80.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	765	765	C	83	C	76	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	88	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1061	17.8	0	.	p	.	0	H217N	NONSYN	649	651	CAT	798	800	AAT	12;12;12	A;A;T	10;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	88	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1061	17.8	0	.	p	.	0	D218N	NONSYN	652	654	GAT	801	803	AAT	11;11;11	A;A;T	8;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	88	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1061	17.8	0	.	p	.	0	V226A	NONSYN	676	678	GTA	825	827	GCA	9;9;9	G;C;A	8;8;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	88	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1061	17.8	0	.	p	.	0	.	MULTIPLE	700	702	ACT	848	850	GTA	9;9;9	G;T;A	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	88	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1061	17.8	0	.	p	.	0	S236N	NONSYN	706	708	AGC	854	856	AAC	9;9;9	A;A;C	8;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	88	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1061	17.8	0	.	p	.	0	.	MULTIPLE	709	711	AAC	858	862	TGGCG	9;9;9;9;9	T;G;G;C;G	9;8;8;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	88	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1061	17.8	0	.	p	.	0	D238A	NONSYN	712	714	GAT	864	866	GCT	9;9;9	G;C;T	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	88	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1061	17.8	0	.	p	.	0	V258L	NONSYN	772	774	GTA	924	926	TTA	9;9;9	T;T;A	8;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	88	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1061	17.8	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	969	971	CAT	10;10;10	C;A;T	9;9;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	88	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1061	17.8	0	.	p	.	0	D274S	NONSYN	820	822	GAT	972	974	AGT	10;9;9	A;G;T	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	88	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1061	17.8	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	981	983	TAC	9;9;9	T;A;C	8;8;7	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	2016	111.7	0	.	p	.	0	T26A	NONSYN	76	78	ACC	630	632	GCC	174;175;175	G;C;C	150;148;145	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	2016	111.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	666	668	GAA	170;171;171	G;A;A	150;155;152	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	2016	111.7	0	.	p	.	0	N124S	NONSYN	370	372	AAT	924	926	AGT	164;164;164	A;G,C;T	143;144,1;142	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	2016	111.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	954	956	GAT	163;161;161	G;A;T	143;145;146	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	2016	111.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1077	1079	TCA	154;154;153	T;C;A	140;140;137	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	2016	111.7	0	.	p	.	0	D212Y	NONSYN	634	636	GAT	1188	1190	TAT	157;156;155	T;A;T	135;134;130	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	2016	111.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1206	1208	GTC	150;149;149	G;T;C	136;136;134	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	2016	111.7	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1218	1220	TCT	148;148;148	T;C;T	130;130;130	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	2016	111.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1536	1538	GCA	133;134;132	G;C,T;A	122;121,1;123	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	2016	111.7	1	SNP	p	G120K	1	.	.	358	360	AAG	912	914	AAG	166;167;167	A;A;G,A,T	144;144;141,1,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	2016	111.7	1	SNP	p	D121N	0	.	.	361	363	GAC	915	917	GAC	167;167;166	G;A;C	146;146;148	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	762	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	2016	111.7	1	SNP	p	A121D	1	.	.	361	363	GAC	915	917	GAC	167;167;166	G;A;C	146;146;148	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2456	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5337	137.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2209	2211	CAT	144;143;143	C;A;T,G	132;132;130,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	406	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1383	87.2	1	SNP	p	V57M	1	.	.	169	171	ATG	704	706	ATG	153;153;154	A;T;G	139;141;142	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
